Modulation of the Immune Response to Androgen Deprivation and Radiation Therapy for the Treatment of Prostate Cancer
Abstract
Although the combination of radiation therapy and androgen deprivation therapy (ADT) is initially effective in many patients, biochemical failure rates of 20% at 5-years to 50% at 10-years have been reported, highlighting the need for improved treatments, particularly for men with high-risk prostate cancer. ADT in the neo-adjuvant setting is used to reduce tumor volume and improve the response to radiation. Additionally, ADT causes infiltration of lymphocytes into the prostate. B cell infiltrates may promote prostate cancer progression and development of castration resistant prostate cancer by the production of inflammatory cytokines and skewing CD4+ T cell responses towards Th2. We hypothesized that depletion of B cells at the time of castration would improve tumor control. Our results demonstrate that the depletion of B cells at the time of castration improves tumor latency.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2013
- Accession Number
- ADA577215
Entities
People
- Lisa D. Johnson
Organizations
- BC Cancer Agency